SuperworthGE HealthCare Technologies GEHC
- Market cap
- $32.3B
- PE
- 16.4×
- 3y median 17.0×
- Forward PE
- 13.8×
- 4y median 17.7×
- Price to sales
- 1.5×
- EV/EBIT
- 14.7×
- Revenue, 12 months
- $21.3B
- +7% on a year ago
- Net margin
- 9.3%
- Free cash flow yield
- 4.9%
GE HealthCare Technologies trades at 16.4× trailing earnings, near its ten-year median. Revenue was $21.3B over the last twelve months, up 7% on a year earlier with a 9% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $4.8B+5% | $5.2B+5% | $4.7B−1% | $4.8B+1% | $4.9B+1% | $5.3B+2% | $4.8B+3% | $5B+4% | $5.1B+6% | $5.7B+7% | $5.1B+7% | $5.3B+6% | |
| Cost of revenue | $2.9B+3% | $3B+2% | $2.7B−2% | $2.8B−1% | $2.8B−2% | $3B−0% | $2.8B+1% | $3B+7% | $3.2B+11% | $3.4B+13% | $3.2B+14% | $3.1B+3% |
| Gross profit | $1.9B+9% | $2.2B+12% | $1.9B+1% | $2B+3% | $2B+5% | $2.3B+6% | $2B+6% | $2B−1% | $2B−2% | $2.3B−1% | $2B−2% | $2.2B+10% |
| R&D | $322M+24% | $315M+16% | $324M+20% | $327M+10% | $316M−2% | $344M+9% | $344M+6% | $302M−8% | $292M−8% | $323M−6% | $345M+0% | $323M+7% |
| SG&A | $996M+10% | $1.2B+30% | $1B−2% | $1.1B−1% | $1B+4% | $1.1B−2% | $1B+0% | $1B−4% | $1B+1% | $1.1B−2% | $1.1B+7% | $1.1B+9% |
| $617M+2% | $689M−11% | $540M−3% | $608M+7% | $676M+10% | $801M+16% | $629M+17% | $654M+8% | $653M−3% | $827M+3% | $515M−18% | $739M+13% | |
| Interest expense | $138M+6800% | $131M+122% | $122M−10% | $131M−4% | $130M−6% | $121M−8% | $110M−10% | $113M−14% | $111M−15% | $105M−13% | $96M−13% | $114M+1% |
| Pre-tax income | $636M+2% | $609M−15% | $512M−6% | $578M+1% | $658M+4% | $834M+37% | $692M+35% | $613M+6% | $643M−2% | $821M−2% | $505M−27% | $693M+13% |
| $250M+94% | $193M+28% | $124M−24% | $143M+4% | $168M−33% | $96M−50% | $104M−16% | $113M−21% | $179M+7% | $219M+128% | $94M−10% | $119M+5% | |
| Net income | $375M−23% | $403M−27% | $374M+1% | $428M+2% | $470M+25% | $721M+79% | $564M+51% | $486M+14% | $446M−5% | $589M−18% | $389M−31% | $561M+15% |
| $0.82−23% | $0.88−28% | $0.81+98% | $0.93+2% | $1.02+24% | $1.57+78% | $1.23+52% | $1.06+14% | $0.98−4% | $1.29−18% | $0.85−31% | $1.24+17% | |
| 458M+1% | 458M+1% | 459M+0% | 459M+0% | 459M+0% | 459M+0% | 459M+0% | 458M−0% | 457M−0% | 458M−0% | 457M−0% | 454M−1% |
EPS, diluted: 4 periods, Q4 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY22 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $5.4B | $5.3B to $5.4B | $1.20 | $1.18 to $1.24 | 12 |
| Q4 FY26 | $5.9B | $5.9B to $6B | $1.60 | $1.58 to $1.64 | 10 |
| Q1 FY27 | $5.4B | $5.3B to $5.4B | $1.12 | $1.10 to $1.14 | 8 |
| Q2 FY27 | $5.5B | $5.4B to $5.6B | $1.25 | $1.22 to $1.27 | 8 |
| Q3 FY27 | $5.6B | $5.5B to $5.7B | $1.35 | $1.33 to $1.37 | 8 |
| Q4 FY27 | $6.2B | $6.1B to $6.3B | $1.74 | $1.71 to $1.76 | 8 |
| Q1 FY28 | $5.5B | $5.4B to $5.6B | $1.31 | $1.29 to $1.33 | 9 |
| Q2 FY28 | $5.6B | $5.5B to $5.6B | $1.41 | $1.38 to $1.43 | 9 |
Peers
Companies in Medical - Devices nearest GE HealthCare Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GEHCGE HealthCare Technologies | $32.3B | 16.4× | 17.0× | 13.8× | 1.5× | +7% | 9.3% |
| DXCMDexCom | $29.4B | 30.9× | 102× | 27.7× | 5.9× | +16% | 20.1% |
| EWEdwards Lifesciences | $51.3B | 51.2× | 40.3× | 28.3× | 7.9× | +15% | 15.4% |
| ZBHZimmer Biomet | $18.8B | 24.0× | 31.4× | n/m | 2.2× | +9% | 9.5% |
| BSXBoston Scientific | $66.2B | 18.5× | 67.0× | 14.1× | 3.2× | +14% | 17.5% |
| SYKStryker | $117.8B | 31.8× | 41.2× | 19.3× | 4.6× | +8% | 14.4% |
| MDTMedtronic | $122B | 23.4× | 28.2× | 15.9× | 3.3× | +10% | 13.9% |
| ABTAbbott Laboratories | $179.4B | 38.7× | 36.7× | 17.7× | n/m | n/m | n/m |
| LIVNLivaNova | $4.5B | 23.9× | 72.5× | n/m | 3.0× | +12% | 12.8% |
| ITGRInteger | $4.3B | 34.6× | 33.5× | n/m | 2.3× | +3% | 7.0% |
| Peer median | $51.3B | 30.9× | 40.3× | 18.5× | 3.2× | +11% | 14.2% |
Investors who own it
Investors we follow who held GE HealthCare Technologies at the end of Jun 30, 2026, from their 13F filings.
- Bill NygrenHarris Associates (Oakmark)1.3% of portfoliotrimmed
- Chris BloomstranSemper Augustus0.0% of portfolio
More on GE HealthCare Technologies
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 13Medical device stocks with the lowest PE ratio
- #2of 13Medical device stocks with the lowest EV/EBIT
- #9of 51Healthcare stocks with the lowest forward PE
- #7of 34Healthcare stocks with the lowest PEG ratio
- #7of 26Medical device stocks with the lowest price to sales ratio
- #5of 13Medical device stocks with the highest free cash flow yield
- #10of 17Medical device stocks with the highest profit margins
- #9of 12Medical device stocks with the fastest earnings growth
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .